Who makes [S,S]-reboxetine monotherapy?

[S,S]-reboxetine monotherapy is developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc..

What development phase is [S,S]-reboxetine monotherapy in?

[S,S]-reboxetine monotherapy is in Phase 2.

Last reviewed 2026-04-19 · How we verify

[S,S]-reboxetine monotherapy

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Phase 2 active Small molecule

At a glance

Generic name	[S,S]-reboxetine monotherapy
Sponsor	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[S,S]-reboxetine monotherapy CI brief — competitive landscape report
[S,S]-reboxetine monotherapy updates RSS · CI watch RSS
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. portfolio CI